TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2139858

Group type: EXPERIMENTAL
Intervention: terfenadine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 30

Group type: COMPARATOR
Intervention: distilled water challenge (control)
Number of subjects: 30
Study: 375178

Group type: EXPERIMENTAL
Intervention: Heparinized fluids (1 unit/ml)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nonheparinized fluids
Number of subjects: 62
Study: 30652949

Group type: EXPERIMENTAL
Intervention: Speed of processing (SOP) training with transcranial direct current stimulation (tDCS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 66
Study: 30609322

Group type: EXPERIMENTAL
Intervention: Violet noise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Brown noise
Number of subjects: 24
Study: 28067762

Group type: EXPERIMENTAL
Intervention: 12% carbohydrate solution (CHO)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-caloric taste matched placebo (PLA)
Number of subjects: 16
Study: 25772627

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 105
Study: 23810332

Group type: EXPERIMENTAL
Intervention: Sequential chemoradiation
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Alternating chemoradiation
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Quality assurance program
Number of subjects: 271
Study: 21672303

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty (BT)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Standard medications and sham BT treatment
Number of subjects: 421
Study: 19220774

Group type: EXPERIMENTAL
Intervention: IL13 p.R130Q and c.1‐1111C>T variants
Number of subjects: 453
Study: 17023001

Group type: EXPERIMENTAL
Intervention: Unipolar depressed in-patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 15088885

Group type: EXPERIMENTAL
Intervention: Scaling and root planing followed by local application of doxycycline (SRP-D)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 43
Study: 11576155

Group type: EXPERIMENTAL
Intervention: ST/HR slope ≤‐2.4 μV · bpm‐1
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: ST-deficit
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cumulative HR adjusted criteria
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Mean ST-deficit
Number of subjects: 116
Study: 9572419

Group type: EXPERIMENTAL
Intervention: 150 IU rhFSH
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 9175962

Group type: EXPERIMENTAL
Intervention: 1% Diprivan mixed with 1% lignocaine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 1% Diprivan mixed with hydrochloric acid
Number of subjects: 71

Group type: COMPARATOR
Intervention: 1% Diprivan mixed with saline
Number of subjects: 71
Study: 1903616

Group type: EXPERIMENTAL
Intervention: Pentigetide, 0.5%, ophthalmic solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cromolyn sodium, 4%, ophthalmic solution
Number of subjects: 50
Study: 7033782

Group type: EXPERIMENTAL
Intervention: Adjusted doses of heparin
Number of subjects: 106

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 106
Study: 31103129

Group type: EXPERIMENTAL
Intervention: Thoracic spine self-mobilization
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo thoracic spine self-mobilization
Number of subjects: 52
Study: 28735778

Group type: EXPERIMENTAL
Intervention: Yoga classes led by a certified instructor twice weekly for 12 weeks, with home practice.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Delayed yoga treatment (control group).
Number of subjects: 150

Group type: COMPARATOR
Intervention: Both groups (yoga and control).
Number of subjects: 150
Study: 26423915

Group type: EXPERIMENTAL
Intervention: Intervention group (alert in medical files and letters to patients and providers)
Number of subjects: 411

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 411
Study: 25445079

Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) for PTSD plus BRENDA
Number of subjects: 137

Group type: COMPARATOR
Intervention: BRENDA alone
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL) for AD
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo (PBO) for AD
Number of subjects: 137
Study: 22971118

Group type: EXPERIMENTAL
Intervention: Aura‐i
Number of subjects: 120

Group type: COMPARATOR
Intervention: air‐Q
Number of subjects: 120

Group type: COMPARATOR
Intervention: air‐Q (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aura‐i (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aura‐i and air‐Q
Number of subjects: 120
Study: 19778775

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stent (BES)
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 1707
Study: 17868436

Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program (CSEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychosocial Education Program (PSEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercise Program with Psychosocial Education (CSEP + PSEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Exercise Program (TEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Exercise Program with Psychosocial Education (TEP + PSEP)
Number of subjects: 0
Study: 15221063

Group type: EXPERIMENTAL
Intervention: Surgical treatment (tailored resection, including microsurgical lesionectomy, lesionectomy plus cortectomy, and hippocampectomy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hippocampectomy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Early operation after seizure manifestation (within 2 years)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Unifocal seizure onset
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resection of one lesion in patients with multiple cavernomas
Number of subjects: 30
Study: 11233456

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 635

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Both sertraline and imipramine
Number of subjects: 635
Study: 9374947

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once-a-day
Number of subjects: 198

Group type: COMPARATOR
Intervention: Diltiazem slow release formulation (SR) 90 mg twice daily
Number of subjects: 198
Study: 1556489

Group type: EXPERIMENTAL
Intervention: Three fractions per week radiotherapy
Number of subjects: 734

Group type: COMPARATOR
Intervention: Five fractions per week radiotherapy
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Salvage laryngectomy after local recurrence
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: Local recurrence
Number of subjects: 734
Study: 3890575

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chloroquine plus primaquine
Number of subjects: 40
Study: 31229466

Group type: EXPERIMENTAL
Intervention: Netarsudil/Latanoprost FDC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Netarsudil 0.02%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 0
Study: 29562151

Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy
Number of subjects: 1472

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 1472
Study: 27169634

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011, 8×10^9 CFU daily)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 24028316

Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no text message reminders)
Number of subjects: 42
Study: 22245954

Group type: EXPERIMENTAL
Intervention: aprepitant
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: race
Number of subjects: 18
Study: 19796883

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study: 17631061

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 15716696

Group type: EXPERIMENTAL
Intervention: 10 mg ramipril
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100 mg atenolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12061475

Group type: EXPERIMENTAL
Intervention: Accelerated discharge and home-based rehabilitation (n = 34)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional hospital care (n = 32)
Number of subjects: 66
Study: 10048741

Group type: EXPERIMENTAL
Intervention: Screening group (flexible sigmoidoscopy)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (not attending screening)
Number of subjects: 400
Study: 8700764

Group type: EXPERIMENTAL
Intervention: Fast-setting amalgam
Number of subjects: 23

Group type: COMPARATOR
Intervention: Slow-setting amalgam
Number of subjects: 23
Study: 1887967

Group type: EXPERIMENTAL
Intervention: Atropine 1.2 mg and Neostigmine 2.5 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Atropine 0.6 mg and Edrophonium 1 mg/kg
Number of subjects: 22
Study: 6342748

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus vincristine, dactinomycin, and cyclophosphamide, with or without Adriamycin
Number of subjects: 24
Study: 31586486

Group type: EXPERIMENTAL
Intervention: 5 g test rice
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 20 g test rice
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31187048

Group type: EXPERIMENTAL
Intervention: Icotinib cream (0.5%, 1.0%, 2.0%, and 4.0%) applied twice daily for 4 weeks
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Icotinib cream (2.0% concentration)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 41
Study: 29796741

Group type: EXPERIMENTAL
Intervention: Primary closure (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Secondary closure (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 28116167

Group type: EXPERIMENTAL
Intervention: Computerised cognitive rehabilitation using RehaCom software, 45 minutes, three times weekly for six weeks.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control condition (no specific details provided).
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Computerised cognitive rehabilitation group.
Number of subjects: 38
Study: 24193372

Group type: EXPERIMENTAL
Intervention: 4 mg reboxetine (RBX) administered immediately after extinction learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both RBX and PLC groups
Number of subjects: 0
Study: 21879340

Group type: EXPERIMENTAL
Intervention: Fact sheet describing HPV vaccine as preventing cervical cancer only (n=81)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Fact sheet describing HPV vaccine as preventing both cervical cancer and genital warts (n=78)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Traditional TPB components
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Moral norm
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Vaccination intention
Number of subjects: 159
Study: 20920820

Group type: EXPERIMENTAL
Intervention: r-HGH replacement therapy for 6 months
Number of subjects: 60
Study: 16971899

Group type: EXPERIMENTAL
Intervention: 20 mg citalopram
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15882785

Group type: EXPERIMENTAL
Intervention: Judoists (head upright vs tilted)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dancers (head upright vs tilted)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Untrained participants (head upright vs tilted)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: VFI participants (experts and untrained)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: VFD participants (experts)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: VFD participants (untrained)
Number of subjects: 12
Study: 12109715

Group type: EXPERIMENTAL
Intervention: Deltamethrin-treated sheets
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Permethrin-treated sheets
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Alphacypermethrin-treated sheets
Number of subjects: 88

Group type: COMPARATOR
Intervention: Untreated sheets (placebo)
Number of subjects: 88
Study: 9678313

Group type: EXPERIMENTAL
Intervention: Dopaminergic drugs
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (primarily clonazepam)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Adverse effects of drug trials
Number of subjects: 147
Study: 8083270

Group type: EXPERIMENTAL
Intervention: Osteotomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Anatomical reduction with AO dynamic hip screw
Number of subjects: 100
Study: 2646357

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 30946478

Group type: EXPERIMENTAL
Intervention: App A (selected based on users' needs)
Number of subjects: 61

Group type: COMPARATOR
Intervention: App B (app with the highest number of users worldwide)
Number of subjects: 61
Study: 26607361

Group type: EXPERIMENTAL
Intervention: Intravenous regadenoson 100 μg (3 doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous regadenoson 200 μg (3 doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous regadenoson 400 μg (2 doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride, 2 or 3 doses)
Number of subjects: 36
Study: 25984779

Group type: EXPERIMENTAL
Intervention: Electrocoagulation
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel (Ultracision)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Radiofrequency dissector (LigaSure)
Number of subjects: 65
Study: 22329914

Group type: EXPERIMENTAL
Intervention: GSK233705 200 µg
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: GSK233705 12.5 µg, 25 µg, 50 µg, 100 µg
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study: 20939213

Group type: EXPERIMENTAL
Intervention: PGE2 intracervical gel 0.5 mg (maximum of 3 doses, every 6 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vaginal insert of PGE2 (single dose for 24 hours)
Number of subjects: 50
Study: 18292959

Group type: EXPERIMENTAL
Intervention: Oral antibiotic prophylaxis with a single 400‐mg dose of norfloxacin
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo (norfloxacin placebo)
Number of subjects: 262
Study: 16104905

Group type: EXPERIMENTAL
Intervention: Betamethasone cream 0.1% applied locally to neurovascular bundles (NVBs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual BNS-RRP with no corticoid cream
Number of subjects: 60
Study: 11796177

Group type: EXPERIMENTAL
Intervention: captopril 37.5 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: imidapril 5 mg
Number of subjects: 79

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 79
Study: 10067997

Group type: EXPERIMENTAL
Intervention: Surgery with a tourniquet
Number of subjects: 77

Group type: COMPARATOR
Intervention: Surgery without a tourniquet
Number of subjects: 77
Study: 7486076

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 90
Study: 2178381

Group type: EXPERIMENTAL
Intervention: Betaxolol 40 mg once daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: Propranolol 40 mg 4 times daily
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both Betaxolol and Propranolol
Number of subjects: 92
Study: 6106099

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide (PPS) vaccine given before radiation and chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide (PPS) vaccine given before splenectomy
Number of subjects: 0
Study: 31455832

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (post‐tetanic counts of 1‐2)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train‐of‐four counts of 1‐2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade
Number of subjects: 88

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade
Number of subjects: 88
Study: 30408073

Group type: EXPERIMENTAL
Intervention: 20-week school-based physical activity intervention
Number of subjects: 663

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Physically active and fit children
Number of subjects: 663
Study: 26592732

Group type: EXPERIMENTAL
Intervention: IDegAsp (insulin degludec/insulin aspart co-formulation)
Number of subjects: 274

Group type: COMPARATOR
Intervention: IDeg+IAsp (basal insulin degludec once daily and prandial insulin aspart 2-4 times daily)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 274
Study: 24831447

Group type: EXPERIMENTAL
Intervention: Baseline VL <10,000 copies/ml (N = 314)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Baseline VL 10,001-100,000 copies/ml (N = 338)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Baseline VL >100,000 copies/ml (N = 122)
Number of subjects: 1106
Study: 22575768

Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: lifestyle behaviour change
Number of subjects: 52
Study: 20632065

Group type: EXPERIMENTAL
Intervention: Cemented rTKA with a 100‐mm press‐fit stem
Number of subjects: 16
Study: 18753646

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (6-g bolus followed by 2 g per hour infusion)
Number of subjects: 2241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2241
Study: 16370790

Group type: EXPERIMENTAL
Intervention: Mentalization-based intervention
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 9
Study: 12238954

Group type: EXPERIMENTAL
Intervention: Use death from cancer as the primary endpoint
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Causal estimate to adjust for nonattendance and contamination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive estimate to adjust for dilution in follow-up
Number of subjects: 0
Study: 10604408

Group type: EXPERIMENTAL
Intervention: Intensification regimen 2 including perioperative hyperfractionated radiotherapy (9.1 Gy), cisplatin (30 mg/m2 per day), surgical resection with intraoperative radiotherapy boost (7.5 Gy), postoperative radiotherapy (40 Gy to primary site and upper neck, 45 Gy to supraclavicular areas), paclitaxel (135 mg/m2 per 24 hours), and cisplatin (100 mg/m2).
Number of subjects: 43
Study: 7542992

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Loratadine 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg/day
Number of subjects: 30
Study: 2117846

Group type: EXPERIMENTAL
Intervention: Continuous nitroglycerin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent therapy with nitrate-free interval
Number of subjects: 0
Study: 7253081

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 31288028

Group type: EXPERIMENTAL
Intervention: SIC-8000
Number of subjects: 158

Group type: COMPARATOR
Intervention: hetastarch
Number of subjects: 158
Study: 27550959

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone gel daily for 14 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo gel daily for 14 weeks
Number of subjects: 62
Study: 24286198

Group type: EXPERIMENTAL
Intervention: Anterior 180° fundoplication
Number of subjects: 47

Group type: COMPARATOR
Intervention: Posterior 270° fundoplication
Number of subjects: 47
Study: 24500661

Group type: EXPERIMENTAL
Intervention: Propofol Group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sevoflurane Group
Number of subjects: 66
Study: 22210007

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for 5 days
Number of subjects: 24
Study: 19056603

Group type: EXPERIMENTAL
Intervention: TV with food and nonfood ads (TV-ads)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TV with no ads (TV-no ads)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reading
Number of subjects: 48
Study: 17580194

Group type: EXPERIMENTAL
Intervention: Hospital-based exercise program (n = 15)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Home-based exercise program (n = 13)
Number of subjects: 38
Study: 15857272

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (25 g/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cow's milk protein isolate (25 g/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Step I diet (low-fat, high-fiber)
Number of subjects: 32
Study: 12038492

Group type: EXPERIMENTAL
Intervention: Text structural variables (on vs. off the causal chain, active vs. static information, hierarchical structure)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Variation in the type of information contained in the text
Number of subjects: 24
Study: 10401657

Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage within 10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage
Number of subjects: 60
Study: 7758568

Group type: EXPERIMENTAL
Intervention: Filter at the mouth (Spirobac)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No filter
Number of subjects: 0